RAD 2020 Abstracts - Page 5

#203 - Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

K Papp, JC Szepietowski, L Kircik, D Toth, ME Kuligowski, M Venturanza, K Sun, E Simpson

#205 - Red in the face: Dupilumab facial dermatitis in a 12 year old boy

Kristina M. Derrick, Sharon A. Glick

#206 - Dupilumab is associated with disease worsening or unmasking of Cutaneous T-cell Lymphoma

ML Espinosa, MT Nguyen, A Saenz Agirre, ME Martinez-Escala, J Kim, CJ Walker, DS Pontes, JI Silverberg, Choi MD, B Pro, LB Pincus, J Guitart, XA Zhou

#209 - Product of Investigator Global Assessment and body surface area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index (EASI) to assess atopic dermatitis severity in children

TP Suh, D Ramachandran, V Patel, KL Jackson, SM Rangel, AB Fishbein, AS Paller

#211 - Association of Chronic Hand Eczema with Anxiety and Depression: A Systematic Review

A Ahmed, M Ayasse, M Yousaf, A Yousaf, J Silverberg

#212 - Association and Impact of Atopic Dermatitis Out-Of-Pocket Healthcare Expenses with Disease Severity and Control

W Smith Begolka, Isabelle Thibau, J Silverberg

#213 - Itch-dominant atopic dermatitis: a distinct phenotype of atopic dermatitis

R Chovatiya, J Silverberg

#214 - Atopic Dermatitis Search Strategy Variation Among Systematic Reviews

Marissa Ayasse, BS, Adnan Ahmed, BS , Muhammad Yousaf, BA, Jonathan I. Silverberg, MD, PhD, MPH

#215 - Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS)

Amy S. Paller, Elaine C. Siegfried, Melinda Gooderham, Lisa A. Beck, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, Heribert W. Staudinger, Xian Sun, Brad Shumel

© 2021 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.